Leads To Development Joins Clarenta Group, Strengthening Early-Stage Drug Development Expertise

Clarenta Group has announced that Leads To Development (L2D) has joined its ranks following a majority investment. This move is set to enhance Clarenta's capacity to assist biotech and pharmaceutical sponsors, particularly from the preclinical drug development phase through to the first-in-human clinical trials.

L2D, based in France, excels in non-clinical development, manufacturing, and regulatory strategy at pivotal early drug development stages. Their expertise aligns with Clarenta’s efforts to connect early scientific strategies with clinical research.

This collaboration arrives shortly after Clarenta's rebranding, marking a strategic expansion. L2D remains in Paris and continues to support clients, benefiting from Clarenta’s extensive capabilities.

Dr. Chris Smyth, CEO of Clarenta, emphasized the importance of this partnership for navigating development complexities. Jonathan Kearsey of L2D highlighted the combined strengths in early-stage development.